Overall, this work elucidates a novel CRLF1-SIN1/AKT-pyroptosis axis that drives chemoresistance in ovarian cancer, firmly establishing CRLF1 as a promising therapeutic target warranting further exploration. This evidence concerns the gene AKT1 and ovarian cancer.